{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-038764","form_type":"8-K","ticker":"CURX","cik":"0002025942","company_name":"Curanex Pharmaceuticals Inc","filed_at":"2026-08-17T20:45:24+00:00","discovered_at":"2026-08-17T20:46:01.541716+00:00","generated_at":"2026-08-17T20:46:12.477000+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Curanex Pharmaceuticals announces 1-for-20 reverse stock split effective Aug 20, 2026","bullets":["1-for-20 reverse stock split effective 12:01 a.m. PT on Aug 20, 2026; Nasdaq trading begins split-adjusted that day.","Pre-split shares ~31,364,812; post-split ~1,568,241 shares outstanding.","Purpose: regain compliance with Nasdaq's $1.00 minimum bid price rule (Listing Rule 5550(a)(2)).","No fractional shares; fractional interests rounded up to whole share; new CUSIP number assigned.","Authorized shares remain 475,000,000; par value $0.0001 unchanged; equity awards proportionally adjusted."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-038764","json":"https://secwatch.observer/filing/0001493152-26-038764.json","markdown":"https://secwatch.observer/filing/0001493152-26-038764.md","text":"https://secwatch.observer/filing/0001493152-26-038764.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2025942/000149315226038764/0001493152-26-038764-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2025942/000149315226038764/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-17T20:46:12.477000+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}